Trial intelligence / Profile preview

PULSE maintenance avelumab in advanced or metastatic squamous cell penile carcinoma

2024-514997-27-00Phase 2Authorised

Sponsor: CHRU Nancy
Start: Dec 2024
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 2, open-label, single-arm trial of avelumab in penile squamous cell carcinoma (PSCC), sponsored by CHRU Nancy. Primary endpoint: Disease-free progression. Planned start Dec 2024; status: authorised.

Drugs

avelumab

Conditions

penile squamous cell carcinoma (PSCC)

Beyond the preview

Go deeper on 2024-514997-27-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514997-27-00.